Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Cognitive Dysfunction in Glioma Patients
NCT03728673Phase 2Recruiting
- Sponsor
- University of Nebraska
- Start
- Mar 2019
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Escitalopram oxalate oral solution in cognitive impairment, sponsored by University of Nebraska. Primary endpoints: Change in Cognition at 17 weeks, Characterize the degree of change in cognition and brain function at 17 weeks and 3 more. Started Mar 2019; status: recruiting.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT03728673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728673.